Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT04487236
• Recruitment Status: Recruiting
• First Posted: July 27, 2020
• Last Update Posted: October 12, 2022
• Sponsor: Suzhou Zanrong Pharma Limited
• Information provided by (Responsible Party): Suzhou Zanrong Pharma Limited

Tracking Information

• First Submitted Date: July 10, 2020
• First Posted Date: July 27, 2020
• Last Update Posted Date: October 12, 2022
• Actual Study Start Date: October 15, 2020
• Estimated Primary Completion Date: December 30, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 9, 2022)

• The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1a [ Time Frame: 23days ]
  Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
• The safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1b [ Time Frame: 21days ]
  Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
• The safety of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1c [ Time Frame: through study completion, an average of 3 year ]
  To evaluate the safety of ZN-A-1041 in combination with Capecitabine in patients on the RP2D Dose

Original Primary Outcome Measures (submitted: July 22, 2020)

• The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1a [ Time Frame: 23days ]
  Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
• The safety/tolerability of ZN-A-1041 in combination with Capecitabine on Phase 1b [ Time Frame: 21days ]
  Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
• The safety of ZN-A-1041 in combination with Capecitabine on Phase 1c [ Time Frame: through study completion, an average of 3 year ]
  To evaluate the safety of ZN-A-1041 in combination with Capecitabine in patients on the RP2D Dose

Current Secondary Outcome Measures (submitted: October 9, 2022)

• Plasma Level of ZN-A-1041 and its major metabolites on phase 1a,phase 1b and 1c [ Time Frame: From baseline to Day 8 ]
  To assess the AUC of ZN-A-1041 and its major metabolites;
• Plasma Level of ZN-A-1041 and its major metabolites on Phase 1a,phase 1 b and 1c [ Time Frame: From baseline to Day 8 ]
  To assess the Cmax of ZN-A-1041 and its major metabolites;
• Plasma level of ZN-A-1041 and its main metabolites Phase 1a,phase 1b and 1c [ Time Frame: From baseline to Day 8 ]
  To assess the Tmax of ZN-A-1041 and its major metabolites;
• The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a,phase 1b and 1c [ Time Frame: through study completion, an average of 3 year ]
  overall Response Rate (ORR);Progression free survival(PFS)

Original Secondary Outcome Measures (submitted: July 22, 2020)

• Plasma Level of ZN-A-1041 and its major metabolites on phase 1a,phase 1b and 1c [ Time Frame: From baseline to Day 8 ]
  To assess the AUC of ZN-A-1041 and its major metabolites;
• Plasma Level of ZN-A-1041 and its major metabolites on Phase 1a,phase 1 b and 1c [ Time Frame: From baseline to Day 8 ]
  To assess the Cmax of ZN-A-1041 and its major metabolites;
• Plasma level of ZN-A-1041 and its main metabolites Phase 1a,phase 1b and 1c [ Time Frame: From baseline to Day 8 ]
  To assess the Tmax of ZN-A-1041 and its major metabolites;
• The preliminary efficacy of ZN-A-1041 as a monotherapy or combination with with Capecitabine on Phase 1a,phase 1b and 1c [ Time Frame: through study completion, an average of 3 year ]
  overall Response Rate (ORR);Progression free survival(PFS)

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
• Official Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

Brief Summary

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.

The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

Detailed Description

Phase 1a of the study will adopt the "modified 3+3" dose escalation design with a total of 7 planned dose levels. Patients with HER2-positive advanced solid tumor (including those with brain metastases) will be enrolled to receive a single-dose administration of ZN-A-1041 followed by multiple-dose administration of ZN-A-1041.

Phase 1b of the study will adopt the "traditional 3+3" dose escalation design. In phase 1b, patients with HER2-positive advanced breast cancer (including those with brain metastases) will be enrolled to receive multiple doses of ZN-A-1041 in combination with Capecitabine and Trastuzumab.

In phase 1c patients with HER2-positive breast cancer with brain metastases were planned to be enrolled to receive ZN-A-1041 in combination with Capecitabine and Trastuzumab The dose levels will be determined based on the recommended doses obtained from the Phase 1b study, and the possible changes in the dosage form and the food effect study, which will be decided by the sponsor and the investigator after discussion.

Each phase of the study includes a screening period, a treatment period and a follow-up period. During the trial, the safety, tolerability, PK and efficacy data of ZN-A-1041 as monotherapy and in combination with Capecitabine and Trastuzumab in the subjects will be collected and analyzed, thereby providing RP2D for the subsequent clinical trials.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Sequential Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Advanced Solid Tumors
• HER2-positive Breast Cancer

Intervention

• Drug: ZN-A-1041 50mg BID
  Orally 21days for one cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 100mg BID
  Orally 21days for one cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 200mg BID
  Orally 21days for one cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 400mg BID
  Orally 21days for one cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 600mg BID
  Orally 21days for one cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 800mg BID
  Orally 21days for one cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 1000mg BID
  Orally 21days for one cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
  Other Name: ZN-A-1041 Enteric Capsules
• Drug: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
  Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
  Other Name: ZN-A-1041 Enteric Capsules

Study Arms

• Experimental: ZN-A-1041 50mg

  Phase 1a:

  Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle

  Intervention: Drug: ZN-A-1041 50mg BID
• Experimental: ZN-A-1041 100mg

  Phase 1a:

  Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle

  Intervention: Drug: ZN-A-1041 100mg BID
• Experimental: ZN-A-1041 200mg

  Phase 1a:

  Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle

  Intervention: Drug: ZN-A-1041 200mg BID
• Experimental: ZN-A-1041 400mg

  Phase 1a:

  Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle

  Intervention: Drug: ZN-A-1041 400mg BID
• Experimental: ZN-A-1041 600mg

  Phase 1a:

  Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle

  Intervention: Drug: ZN-A-1041 600mg BID
• Experimental: ZN-A-1041 800mg

  Phase 1a:

  Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle

  Intervention: Drug: ZN-A-1041 800mg BID
• Experimental: ZN-A-1041 1000mg

  Phase 1a:

  Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle

  Intervention: Drug: ZN-A-1041 1000mg BID
• Experimental: ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

  Phase 1b:

  ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.

  Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.

  Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.

  If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  Intervention: Drug: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
• Experimental: ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First Cycle

  Phase 1b:

  ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.

  Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.

  Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.

  If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  Intervention: Drug: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
• Experimental: ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First Cycle

  Phase 1b:

  If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

  If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  Intervention: Drug: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
• Experimental: ZN-A-1041+Capecitabine+Trastuzumab

  Phase 1c:

  The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion

  Intervention: Drug: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: July 22, 2020): 84
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: June 30, 2024
• Estimated Primary Completion Date: December 30, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Key inclusion criteria:

11. ECOG performance status of 0 to 1 2. HER2-positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++).

3. Phase 1a study will enroll patients with unresectable or metastatic HER2-positive advanced solid tumor; Phase 1b study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer.

i. For patients who have no brain metastases, the following criteria should be met:

1. Patients should be relapsed or refractory to existing therapy(ies) or have been intolerant of such therapies
2. Have at least one extracranial measurable lesion by RECIST v1. 1 ii. For patients with brain metastasis, the following criteria should be met:

1) Have received prior treatment or patient declined the above treatment; 2) Patients with HER2-positive gastric cancer must have previously received Trastuzumab 3) Do not require immediate local treatment during the trial period, and meet either of the following two criteria:

1. For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT and 2 weeks from SRS.
2. Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period.

iii. In Phase 1a, for patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. In Phase 1b, for patients who have received previous trastuzumab or other antibodies, the interval between the last treatment and the first administration of the study drug in this trial should be at least 3 weeks.

4. Phase 1c study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer with brain metastases.

i. For patients with brain metastasis, patients do not require immediate local treatment during the trial period, and meet either of the following two criteria:

1. For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT, 2 weeks from SRS and 4 weeks from surgery
2. Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period
3. Have at least one measurable lesion and is suitable for accurate repeated assessable by RECIST 1.1, and the patient has an imaging-diagnosable intracranial lesion;
4. Patients should not include suspected or confirmed meningeal metastases;
5. The patient had no disease progression with previous 12 weeks' capecitabine therapy;
6. No capecitabine therapy within 6 months;
7. Patient should not previously treat with a tyrosine kinase inhibitor (TKI). Previous treatment with trastuzumab or other antibodies should be at least 3 weeks apart from the first treatment

Key exclusion criteria:

1. Subjects who have participated in any clinical study or received any clinical study drug within 4 weeks prior to the first administration
2. There is evidence that other primary tumors are present at the same time;
3. Previous cumulative dose of doxorubicin exceeds 360mg/m2 or its equivalent dose of similar drugs;

4. CNS Exclusion - Based on screening brain MRI and clinical assessment

   1. Progressive neurologic impairment or increased intracranial pressure (including nausea, vomiting, blurred vision, headache, epilepsy, etc.)
   2. Any intracranial lesion thought to require immediate local therapy
   3. Require antiepileptic treatment (except for these patients with stable seizures require continuous Levetiracetam therapy).
   4. Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Fei Ma, MD; +861087788060; drmafei@126.com

Contact: Qun Yi Li, MD; +861087788120; liyiqun_chcams@foxmail.com

• Listed Location Countries: China

Administrative Information

• NCT Number: NCT04487236
• Other Study ID Numbers: ZN-A-1041-101
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Suzhou Zanrong Pharma Limited
• Original Responsible Party: Same as current
• Current Study Sponsor: Suzhou Zanrong Pharma Limited
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Fei Ma, MD; Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College

• PRS Account: Suzhou Zanrong Pharma Limited
• Verification Date: October 2022